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ABSTRACT 
Objective: To identify patients coming to Emergency Medicine Department (EMD) with drug related problems, classify the DRPs and calculate the 
direct cost spent for treating them. 
Methods: This was a prospective observational study conducted in emergency medicine department. The patients coming to EMD with DRPs were 
classified according to Cipolle’s classification and the direct medical and non-medical costs were calculated. 
Results: A total of around 107 patients identified with DRPs of which 99 patients were included in the study. In this study, 51% of the cases were 
due to ADR and 35% due to non-adherence and rest of the cases were due to overdose (10%), drug interaction (3%) and sub therapeutic dose (1%). 
Major portion for treatment was spent for direct medical cost in which cost for laboratory investigations have contributed the most, INR 10,93,992 
(42%) followed by Health care professional cost INR 55,6814 (21%), Pharmacy cost INR 4,00,524.6 (15%), Admission cost INR 3,80,400 (15%). The 
direct non-medical cost includes cost for diet and travel which was found to be INR 1,68,443 and INR 71,947 respectively. 
Conclusion: The drug related problems adds a significant economic burden on the patients which can be reduced by imparting knowledge about 
the proper use of medicines and by improving collaborative efforts of the patients, physicians, pharmacists and caregivers. 
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Medications are used in various disease conditions to optimize drug 
therapy with minimum safety-related problems within the 
framework of the pharmaceutical care plan. Over the last few 
decades, advances in drug, therapies have improved patient care and 
there has been an apparent increase in the incidence of Drug-
Related Problems (DRPs) being reported [1]. DRP can be defined as 
an event which may potentially affect the health outcomes in the 
patients. It can occur during any stages of drug use, starting from 
prescribing to administration. Lack of follow-ups may also leads to 
drug-related problems [2]. Various risk factors for DRPs include 
polypharmacy, comorbid diseases, increased medicine use. Another 
major contributing factor is the practice of self-medication with over 
the counter (OTC) medications available in India and many other 
parts of the world [3-5]. 
Even with the combined efforts taken by the manufacturers, regulatory 
authorities and health care professionals to reduce the incidence of 
DRPs, they continue to occur due to various reasons that can be 
attributed to different stages of drug use. DRPs occur in patients because 
of the improper use that might appear at any level of drug use. This 
demands appropriate attention and interventions to reverse the 
condition which might expose a patient to severe harm than the disease 
itself for which one was taking medicine. The severity of DRPs can range 
from minor side effects to the death of the patient. 
Nowadays, a lot of hospital visits and admissions can be attributed 
to DRPs and this rate seems to be rising over the past two decades. 
In the process of reversing the DRPs healthcare resources and a 
significant amount of money is spent, which poses an economic 
burden on the patients as they have to spend more than what was 
intended for their ailment. The economic impact of DRPs is extensive 
on patients, healthcare providers, administrators, and society. 
Estimates have shown that for every US $1 spent on drugs, US $1.33 
is consumed to treat DRPs [6]. The cost of DRP has increased every 
year and in 2008 it was estimated at US $289 billion in the United 
States [7]. An Indian study showed total cost for the management of 
DRPs was calculated to be INR17,37,339. The direct cost was INR 
1,72,961 and the approximate indirect cost was INR 15,64,378. The 
drugs used for treatment (54%) contribute a significant part in 
direct cost. Among various drug-related problems, medication non-
adherence was the main contributor (85% of total cost) followed by 
adverse drug reactions (13% of total cost) [8]. 
In a developing country like ours, the majority of the population 
belongs to the middle class with only sufficient money for their day 
to day living and do not have medical insurance coverage. Also, most 
of the medications are available as OTC drugs and lack of qualified 
pharmacy professionals for handling the medicine. Therefore, 
creating a clear picture of hospital visits due to drug-related 
problems and its economic impact is significant. Even though a 
number of studies have evaluated the pharmacoeconomic impact of 
DRPs in the developed world, only limited data are available from 
developing countries. 
MATERIALS AND METHODS 
In our study, we have attempted to calculate 
the direct cost involved to treat patients who present to the 
Emergency Department because of DRPs. 
A prospective observational study was conducted over a period of 
six months in the Emergency medicine Department of PSG Hospitals, 
Peelamedu, Coimbatore. The study was approved by the Institution 
Human Ethics Committee (IHEC, PSG IMSR) of the hospital. The 
protocol was approved on 26/2/2018, Proposal number: 18/077. 
Patients came to emergency medicine department with drug-related 
problems were selected for the study. Both genders and all age 
groups were included. Critically ill patients, patients who are not 
willing to participate and patient’s with claim or insurance were 
excluded from the study. 
Patient data collection form included demographic details, medical 
and medication history, direct medical and non-medical cost. The 
DRPs identified and were categorized based on CIPPOLLEs 
classification, which include Adverse drug reactions (ADR), 
Medication error, Noncompliance, Drug interactions, Untreated 
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indication, Drug use without indication, Improper drug selection, 
Subtherapeutic Dose, Supra therapeutic Dose. The ADR’s were 
classified based on the WHO-UMC scale and preventability of ADR 
was categorized based on the Schumock and Thornton scale. The 
direct cost for each DRPs was calculated. Pharmacy cost, Laboratory 
cost, Admission cost, Health care professional cost were included in 
the direct medical cost, whereas direct non-medical cost included 
Diet and Transport charges. 
RESULTS 
During our study period of 6 mo, 10,485 patients visited the 
emergency department, of which 107 were due to drug-related 
problems. From these cases, 8 were excluded after meeting the 
exclusion criteria and the remaining 99 cases were included in our 
study. 
The DRPs were found to be almost equally predominant in both genders, 
of which 48% were females and 52% were males. The 99 subjects 
enrolled in our study were classified into 5 age groups ranging from 0-
18, 18-29, 40-59, 59-79 and 80-99 y. Most frequent occurrence of DRP 
was observed in the age group 40-59, which was about 45%. 
The DRP’s observed were grouped according to CIPOLLE’s 
classification into 5 categories. The patients included in our study 
experienced different types of drug related problems like adverse 
drug reactions, non-compliance or medication error, drug 
interactions, sub-therapeutic dose and overdose. In this study, 50 
patients were presented with ADR (51%), followed by 35 non- 
adherent to the medicines. Overdose of medications were observed 
in 10 patients (10%), while in 3 patients drug interactions were seen 
(3%) and and a case of sub therapeutic dose was recieved which is 
shown in fig. 1. 
 
 
Fig. 1: Distribution of DRP’s as per cipolle’s classification 
 
In the DRPs, ADR showed the highest prevalence and was seen in 50 
patients (51%). The ADR’s were classified based on the WHO-UMC 
scale and it showed 64% was probable, 32% possible and 4% 
certain. The preventability of ADR was categorized based on the 
Schumock and Thornton scale, which revealed 34% of ADR’s were 
not preventable and 66% were preventable of which 30% were 
definitely preventable which is shown in the fig. 2 and 3. This may be 
due to the selection of drug, dose, route of administration, 
frequency, drug interaction, lack of patient’s knowledge. Of the 99 
cases assessed, 15 subjects were admitted due to DRPs associated 
with anti-diabetics (14%) followed by 14 admissions by anti-
epileptics (13%) and anti-psychotics (13%) each. 
 
 
Fig. 2: Preventability of ADR 
 
Fig. 3: Preventability class,  
 
The direct cost spent in treating DRP’s is an addition of direct 
medical cost and direct non-medical cost. Direct medical cost 
includes pharmacy cost, healthcare professionals cost, laboratory 
cost, admission cost that contributed to almost 92% of the total and 
direct non-medical cost included diet and travel charges. A total 
direct cost of about INR 25,96,007 was spent to treat the patients 
who visit the EMD due to drug-related problems. The patients were 
treated in both inpatient (IP) and outpatient (OP) settings. For 
managing the DRPs for outpatients, INR 75,248 (33% of the total 
direct cost) was spent and for those treated as inpatients, an amount 
of INR 25,20,829 (67% of the total direct cost) was disbursed. A total 
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of INR 23,56,728 was spent for direct medical cost of which, 42% 
comprised of laboratory charges amounting to INR 10,39,992. A 
direct non-medical cost of INR 2,39,349 was spent by the patients 
during our study period.6% of the total direct cost was the amount 
spend towards diet which is the highest contributor in direct non-
medical cost of INR 1,68,443 were shown in table 1. 
 
Table 1: Distribution of DRPs in treatment cost 
Type of cost Total cost (in INR) Percentage (%) Mean Standard deviation (±) 
Direct medical cost 
Pharmacy cost 400524.6 15% 4045.70 17849.91 
Health care professionals cost 556814 21% 5624.38 14280.99 
Laboratory cost 1093992 42% 11050.42 19525.63 
Admission cost 380400 14% 3842.42 11268.86 
Total 2356728.148 92% 23805.33 47071.31 
Direct non-medical cost 
Diet 168443 6% 1701.44 2319.83 
Travel 71947 2% 726.73 768.90 
Total 239349.2 8% 2417.66 2797.86 
Grand total 2596077 100% 26223.00 48568.96 
 
In the total direct cost, 67% was contributed by 66 in-patients 
and 33% by the out-patients. Even though the direct cost for 
inpatients and out-patients was found to be similar, direct non-
medical cost (25%) was found to be a major contributing factor 
for out-patients whereas direct medical cost was substantial for 
in-patients. 
In our study the direct cost spent for ADR was INR 15,20,960 (58%), 
which shows ADR is the highest contributor among the DRPs, then 
comes non adherence with INR 8,32,656 (32%)and for drug-
interaction and overdose it was INR 1,93,888 (6%) and INR 1,23,052 
(4%) respectively. 
The direct cost spent for ADR was about INR 15,20,960, in which 
direct medical cost was INR 13,94,037 and the direct non-medical 
cost was INR 1,26,923. Among various drug-related problem’s 
adverse drug reactions (ADR) was the main contributor (51%) of 
total cost, it was observed that the potential for an adverse reaction 
like cutaneous reaction like rash, generalized pruritus, was 43% 
followed by hepatotoxicity. ATT had the highest potential (44%) for 
an adverse drug reaction followed by steroids (42%). 
Non-adherence to anti-diabetic, anti-epileptics, anti-tubercular, anti-
hypertensive drugs was predominant DRPs reported, which 
escalates the treatment cost especially the direct medical cost. 
Approximately about INR 23790.17 was spent by a patient, in which 
direct medical cost was INR 21501.95 and the direct non-medical 
cost was INR 2288.22. 
The direct cost spent for drug-interaction was about INR 1,93,888, in 
which direct medical cost was INR 1,77,864 and the direct non-
medical cost was INR 16,024. The laboratory cost shows the highest 
percentage was about 53% from the total medical cost. Management 
of drug interaction leading to hospitalization incurred the least 
expenditure was about 3%. 
Among the 10 overdose cases, the major portion of the total cost was 
spent for healthcare professionals (34%), which mainly includes the 
fees for physicians, nurses, and physiotherapist and is about INR 
4238. The direct cost spent for overdose was about INR1,23,0522 in 
which direct medical cost was INR 1,11,60 and the direct non-
medical cost was INR 11,4480 
The direct cost spent for sub-therapeutic dose was about INR 
7972.49 in which direct medical cost was INR 7272.49 and the direct 
non-medical cost was INR 700. 
DISCUSSION 
The prevalence of DRPs was higher in males (52%) than in females 
(48%) which were also comparable to the population in an Indian 
study [8]. About 45% of DRP was observed in the age group 40-59 
which may be due to poor knowledge about the disease and the 
drugs and other risk factors such as poly-pharmacy, co-morbid 
conditions and lack of follow-up and reassessment of medical 
treatment. Similarly, in a study by Baena MI et al., the patients within 
the age group of 45-64 taking 3 or more medicines presented an 
odds ratio of 64.07 [9]. 
Among the various DRPs, ADRs showed the highest prevalence. A 
study by Peter J Zed et al. showed drug-related visits were 
predominantly due to adverse drug reactions, followed by non-
adherence which was almost identical to our findings [10]; while 
overprescribing of the correct medication was found to be the major 
cause in the study by Tafreshi et al. [11]. The distribution of ADRs 
based on preventability showed that most of the ADRs were 
preventable. Adverse drug-related events accounted for 12% of 
emergency department visits, of which 68% were considered 
preventable in the first study [10]. Apart from these, a study from 
Karnataka showed that 47.55% of DRPs are due to drug interaction 
[12]. 
In our study most common drug classes that caused DRPs were anti-
diabetics, anti-psychotics, anti-epileptics. Peter J Zed et al., in one of 
his study identified antimicrobial agents (11.2%), opioid-containing 
analgesics (11.2%), antipsychotics (9.5%) and benzodiazepines 
(6.1%) as the major contributors of DRPs [10]. In his other study in 
2018 the most common drug classes were anti-infectives (27.4%), 
respiratory agents (22.4%), central nervous system agents (20.4%), 
immunosuppressants (7.5%), and gastrointestinal agents (6.0%) 
[13]. A study by Tafreshi revealed the most common medications 
involved were cardiovascular agents, narcotics, antibiotics, asthma 
medications, antidepressants, anti-epileptics, acetaminophen, anti-
Parkinson medications [11]. 
In treating DRPs a significant amount of money is spent and it is 
actually an additional expense to the normal cost of drug use by the 
patients. A study conducted in India by Smita Pattanaik et al., 
showed that the total cost of management of all the 92 drug-related 
events was calculated to be INR 17,37,339. The major share of the 
direct cost was due to the drugs used for the treatment of DRPs 
(54%). In addition, medication noncompliance was the single most 
important contributor to the cost (85% of the total cost), followed 
by ADRs (13% of the total cost), while management of drug 
overdose leading to hospitalization incurred the least expenditure 
[8].  
When a person visits the hospital due to a DRP, if treated in an 
inpatient setting, an average of about INR 38,194.38 is spent and if 
treated as an outpatient, an average of about INR 2,280.243 is spent. 
The patients, based on their DRP’s severity and the amount of 
attention needed to reverse the condition, they are decided whether 
they have to be treated in the outpatient setting or whether they 
have to be treated in the inpatient setting and accordingly the cost 
for the reversal of DRPs vary as mentioned above. Usually, when the 
patient is severely affected, he/she might have to be admitted in the 
hospital in the care of various healthcare professionals to reverse 
the DRP or if the DRP is not that severe, like in allergies caused by 
the drugs, the patient is stabilized and then discharged without 
admission in the hospital. 
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CONCLUSION 
A large portion of DRPs observed were preventable cases of ADRs 
and non-adherence to treatment. The most common drug classes 
involved were anti-diabetics, anti-epileptics, anti-psychotics and 
anti-hypertensive drugs which are used for the predominant 
diseases in India. Laboratory cost was found to be the major 
contributor for direct medical cost. Educating patients about the 
correct use of their medications, showing the importance of 
adherence to treatment could reduce pressures on emergency 
services, hospitalizations, and consequently costs to the hospital, the 
health system, and the society.  
LIMITATIONS OF THE STUDY 
The main limitation of our study is that direct cost is only calculated. 
Indirect cost and intangible cost, which are the significant 
dimensions of cost of illness studies, were not included. 
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